Development and Applications of a Novel, First-in-Class Hyaluronic Acid from Bacillus

Abstract

Since 1934, hyaluronic acid (HA) has been extracted from rooster combs and employed for various applications such as ophthalmic surgery, orthopedic and wound healing. A breakthrough in HA production occurred in 1985, when the more sophisticated streptococcal fermentation process was implemented and considered the 'gold standard' since then. Novozymes Biopolymer radically shifted the paradigm by employing a unique and non-pathogenic strain, Bacillus subtilis, as an industry factory to produce a new biosynthetic HA product: HyaCare ® . HyaCare ® powder is composed of microparticles with enhanced surface properties that improve solubilization time compared to conventional processes. This new technology combined with the molecular and physico-chemical properties of HA provides improved safety, purity, consistency, stability and ease of filtering. HyaCare ® is produced using an advanced fermentation process without ingredients derived from animal sources or organic solvents. It is an extremely pure source of HA in which there are no exotoxins and low level of proteins. These properties make it suitable for use in biomedical and pharmaceutical applications.